| Literature DB >> 32736632 |
Julia Schröders1, Fatwa Sari Tetra Dewi2, Maria Nilsson3, Mark Nichter4, Miguel San Sebastian3.
Abstract
BACKGROUND: Social networks (SN) have been proven to be instrumental for healthy aging and function as important safety nets, particular for older adults in low and middle-income countries (LMICs). Despite the importance of interpreting health outcomes in terms of SN, in many LMICs - including Indonesia - epidemiological studies and policy responses on the health effects of SN for aging populations are still uncommon. Using outcome-wide multi-method approaches to longitudinal panel data, this study aims to outline more clearly the role of SN diversity in the aging process in Indonesia. We explore whether and to what degree there is an association of SN diversity with adult health outcomes and investigate potential gender differences, heterogeneous treatment effects, and effect gradients along disablement processes.Entities:
Keywords: Aging populations; Causal inference; Cognitive function; Disablement process; Instrumental variable; Lower-middle income countries; Non-communicable diseases; Outcome-wide epidemiology; Propensity score matching; Social network diversity
Year: 2020 PMID: 32736632 PMCID: PMC7393827 DOI: 10.1186/s12939-020-01238-9
Source DB: PubMed Journal: Int J Equity Health ISSN: 1475-9276
Overview and assessment of the outcome battery
| 1. Non-communicable disease (NCD) morbidity | Self-reported physician diagnosis1 of any one condition listed #2-#7; “Has a doctor ever told you that you had […]?” | 0 = yes; 1 = no |
| 2. Asthma | Self-reported physician diagnosis1 | 0 = yes; 1 = no |
| 3. Other chronic lung diseases | Self-reported physician diagnosis1 | 0 = yes; 1 = no |
| 4. Cancer or malignant tumours | Self-reported physician diagnosis1 | 0 = yes; 1 = no |
| 5. Diabetes or high blood sugar | Self-reported physician diagnosis1 | 0 = yes; 1 = no |
| 6. Cardiovascular diseases (heart attacks, coronary heart diseases, angina, or other heart problems) | Self-reported physician diagnosis1 | 0 = yes; 1 = no |
| 7. Stroke | Self-reported physician diagnosis1 | 0 = yes; 1 = no |
| 8. Prediabetes or diabetes based on glycosylated haemoglobin (HbA1c) levels2 | Biomarker; Dried blood spots (DBS) based assays taken from trained IFLS interviewers to measure glucose metabolism. | Continuous variable (range: 3.5–12.8%); Binary variable: 0 = yes (diabetes or prediabetes, > 5.7%); 1 = no (normal range < 5.7%)3 |
9. Hypertension | Three measures of systolic and diastolic blood pressure (BP) in mmHg on alternate arms (starting left) by trained IFLS interviewers using an Omron meter (HEM-7203) and self-reported use of antihypertensive medication. | 0 = yes (hypertensive; defined as mean systolic BP ≥140 mmHg and/or mean DBP ≥90 mmHg and/or current use of antihypertensive medication); 1 = no (normotensive)4 |
10. Chronic inflammation based on C-reactive protein (CRP) levels2 | Biomarker; CRP (plasma equivalent) concentrations from finger-prick DBS specimens measured using validated enzyme-linked immunosorbent assay (ELISA) method. | Continuous variable (range: 0.01–58.95 mg/l); Binary variable: 0 = yes (> 1.0 mg/l); 1 = no (normal range < 1.0 mg/l)5 |
11. Mean hand grip strengths | Physical performance test; Hand grip strengths was measured by a trained IFLS interviewer using a Baseline Smedley Spring type dynamometer (daily calibration). Respondents were asked to squeeze the dynamometer in each hand twice beginning with the dominant hand. Two measurements per hand were recorded including information on any recent surgery, swelling, inflammation, severe pain, or injury on one or both hands and recording of dominant hand. | Continuous variable (mean of four measurements, range: 0–47.75 kg) |
| 12. Arthritis and/or rheumatism | Self-reported physician diagnosis1 | 0 = yes; 1 = no |
13. Hearing and/or vision problems | Self-reported physician diagnosis1 | 0 = yes; 1 = no |
14. Upper-body functional limitations (UBFL)6 | Self-reported physical functioning measures; including show cards; Question: “If you had […], could you do it?” 1) to carry a heavy load (like a pail of water) for 20 m 2) to draw a pail of water from a well 3) to sweep the house / floor / yard | 0 = yes (includes responses “with difficulty” and “unable to do it”); 1 = no (“easily”) |
| 15. Lower-body functional limitations (LBFL)7 | Self-reported physical functioning measures; including show cards; Question: “If you had […], could you do it?” 1) to walk 1 km 2) to bow, squat, or kneel 3) to stand up from sitting on the floor without help | 0 = yes (includes responses “with difficulty” and “unable to do it”); 1 = no (“easily”) |
16. Episodic memory score | Cognitive performance test; Immediate and delayed word recall of ten nouns. These were read out slowly and the respondent was asked to repeat the list immediately and again after 4 to 5 min. Questionnaire contained four lists of each ten words which were randomized across individuals within a household. | Continuous variable (mean number of words correctly recalled for both immediate and delayed response; range: 0–8.5 words) |
| 17. Visuospatial ability score | Cognitive performance test; IFLS uses an abridged version of the Raven’s Progressive Matrices8, a non-verbal self-paced test in which each item contained a pattern with a missing part. The respondent had to infer the rules underlying the pattern and apply these rules to discover which of the answer options provides the correct completion for a total of eight items. | Continuous variable (one score point per correct answer; range: 0–8 points) |
| 18. Activities of daily living (ADLs) limitations9 | Self-reported physical functioning measures for five basic tasks of everyday life; including show cards; Question: “If you had […], could you do it?” (1) to dress without help (2) to bathe (3) to get out of bed (4) to eat (eating food by oneself when it is ready) (5) to control urination or defecation | Continuous variable (range 5–25); Binary variable: 0 = yes (includes responses “with difficulty”, “can do with help” and “unable to do it”); 1 = no (“easily”) |
| 19. Instrumental activities of daily living (IADLs) limitations10 | Self-reported ability to perform IADLs items; including show cards); Question: “If you had […], could you do it?” (1) to shop for personal needs (2) to prepare hot meals (prepare ingredients, cooking, and serving food) (3) to take medicine (right portion at right time) (4) to do household chores (house cleaning, doing dishes, making the bed, and arranging the house) (5) to shop for groceries (deciding what to buy and pay for it) (6) to manage your money (paying your bills, keeping track of expenses, or managing assets) | Continuous variable (range 6–30); Binary variable: 0 = yes (includes responses “with difficulty”, “can do with help” and “unable to do it”); 1 = no (“easily”) |
Annotations Table 1:
For more details see Strauss J, Witoelar F, Sikoki B. The Fifth Wave of the Indonesia Family Life Survey (IFLS5): Overview and Field Report. Santa Monica: RAND, 2016 and IFLS questionnaires available at https://www.rand.org/well-being/social-and-behavioral-policy/data/FLS/IFLS.html
1) Includes diagnoses by paramedics, nurses and midwifes
2) HbA1c and CRP values are only available for a sub-sample in IFLS-5. DBS for CRP assays were introduced in IFLS-4 for a random sample of IFLS-1 dynasty households (=9944 respondents above age 1). In IFLS-5, the target sample for repeated CRP assays and (newly introduced) HbA1c was the subset of respondents who had DBS taken in IFLS-4. There are 7579 observations with CRP data and 7524 observations with HbA1c in wave 5. Further details on sampling for the DBS and sampling weights are available in Herningtyas EH, Hu P, Edenfield M, Strauss J, Crimmins E, Witoelar F, et al. IFLS Wave 5 Dried Blood Spot Data User Guide. Santa Monica: RAND, 2018. In our analyses, we have CRP data for 1913 (35%) and HbA1C data for 1887 (34%) respondents
3) Cut-offs based on The International Expert Committee. Report on the role of the A1C assay diagnosis of diabetes. Diabetes Care. 2009 32(7):1327–34
4) Respondents with controlled hypertension (n = 62), uncontrolled hypertension (n = 2262) and hypertension without treatment (n = 33) were classified as hypertensive. Hypertension definition adapted from WHO Expert Committee on Hypertension Control. Hypertension control. Geneva: World Health Organization, 1996
5) Cut-offs are based on Speidl WS, Zeiner A, Nikfardjam M, Geppert A, Jordanova N, Niessner A, et al. An increase of C-reactive protein is associated with enhanced activation of endogenous fibrinolysis at baseline but an impaired endothelial fibrinolytic response after venous occlusion. Journal of the American College of Cardiology. 2005 45 (1):30–4
6) Cronbach’s alpha for three UBFL items = 0.7863
7) Cronbach’s alpha for three LBFL items = 0.7306
8) Raven J. The Raven’s progressive matrices: change and stability over culture and time. Cogn Psychol. 2000 41 (1):1–48
9) Cronbach’s alpha for five ADL items is 0.8319; ADL items adapted from Katz S. Assessing self-maintenance: activities of daily living, mobility, and instrumental activities of daily living. J Am Geriatr Soc. 1983 31 (12):721–7
10) Cronbach’s alpha for six IADL items is 0.9043; IADL items adapted from Lawton, M.P., & Brody, E.M. (1969). Assessment of older people: Self-maintaining and instrumental activities of daily living. The Gerontologist, 9 (3), 179–186
Baseline characteristics of respondents in IFLS-4 (2007/08), stratified by sex/gender
| n (%) or mean ± SD | n (%) or mean ± SD | n (%) or mean ± SD | ||
|---|---|---|---|---|
| SNI score | 4.15 (1.14) | 4.18 (1.02) | 4.12 (1.23) | 0.147 |
| Low SNI | 1840 (60) | 890 (60) | 950 (60) | 0.890 |
| High SNI | 1220 (40) | 587 (40) | 633 (40) | |
| 50–57 years | 1736 (57) | 813 (55) | 923 (58) | 0.069 |
| 57+ years | 1324 (43) | 664 (45) | 660 (42) | |
| No schooling | 553 (18) | 145 (10) | 408 (26) | < 0.001 |
| Elementary school | 1706 (56) | 847 (57) | 859 (54) | |
| High school | 631 (21) | 369 (25) | 262 (17) | |
| University | 170 (6) | 116 (8) | 54 (3) | |
| First (poorest) | 735 (24) | 363 (25) | 372 (23) | 0.336 |
| Second | 783 (26) | 388 (26) | 395 (25) | |
| Third | 770 (25) | 350 (24) | 420 (27) | |
| Fourth (richest) | 772 (25) | 376 (25) | 396 (25) | |
| Rural | 1611 (53) | 812 (55) | 799 (50) | 0.013 |
| Urban | 1449 (47) | 665 (45) | 784 (50) | |
| Moved once or more since 2000 | 280 (9) | 167 (11) | 113 (7) | < 0.001 |
| Did not move since year 2000 | 2780 (91) | 1310 (89) | 1470 (93) | |
| Yes | 1259 (41) | 1132 (77) | 127 (8) | < 0.001 |
| No | 1801 (59) | 345 (23) | 1456 (92) | |
| Obese | 385 (13) | 117 (8) | 268 (17) | < 0.001 |
| Overweight | 1010 (33) | 429 (29) | 581 (37) | |
| Underweight | 1211 (40) | 698 (47) | 513 (32) | |
| Normal weight | 454 (15) | 233 (16) | 221 (14) | |
| Less active | 553 (18) | 236 (16) | 317 (20) | < 0.001 |
| Moderately active | 1503 (49) | 554 (38) | 949 (60) | |
| Vigorously active | 1004 (33) | 687 (47) | 317 (20) | |
| Bad | 548 (18) | 218 (15) | 330 (21) | < 0.001 |
| Good | 2512 (82) | 1259 (85) | 1253 (79) | |
| Yes | 1064 (35) | 528 (36) | 536 (34) | |
| No | 1996 (65) | 949 (64) | 1047 (66) | 0.273 |
| No | 2776 (91) | 1329 (90) | 1447 (91) | 0.173 |
| Yes | 284 (9) | 148 (10) | 136 (9) | |
| No | 2177 (71) | 1033 (70) | 1144 (72) | 0.155 |
| Yes | 883 (29) | 444 (30) | 439 (28) | |
| Multiple NCDs | 25 (1) | 14 (1) | 11 (1) | 0.262 |
| Single NCD | 273 (9) | 121 (8) | 152 (10) | |
| None | 2762 (90) | 1342 (91) | 1420 (89) | |
| ADL and IADL | 256 (8) | 54 (4) | 202 (13) | < 0.001 |
| ADL or IADL | 625 (21) | 152 (10) | 473 (30) | |
| No disability | 2179 (71) | 1271 (86) | 908 (57) | |
Annotations Table 2:
1) Monthly household per capita expenditure in Indonesian rupiah (IDR); the mean household PCE amount equals ca. USD 59 (IDR 1 = USD 0.0001107690 as of midyear 2007)
2) Based on the BMI cut-off points suggested for Asian populations: < 18.48 = underweight; 18.50–22.99 = normal weight; 23.00–27.49 = overweight; > 27.50 = obese. Source: WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004 363(9403):157–63
3) Information taken from IFLS-5 (2014/15)
4) Includes health insurance programmes from ASKES, ASTEK/Jamsostek, employer provided medical reimbursement, employer provided clinic, private health insurance, savings-related insurance, JAMKESMAS, JAMKESDA, JAMKESSOS, JAMPERSAL, or ASURANSI MANDIRI
5) The crude measure of baseline NCD morbidity includes self-reported physician diagnoses of asthma, other chronic lung diseases, cancer or malignant tumours, diabetes or high blood sugar, heart attacks, coronary heart diseases, angina, other heart problems, and strokes
6) In the IFLS questionnaires, three IADL items across wave 4 and wave 5 were not identical. The following items have been compared in IFLS-4 and IFLS-5, respectively: (i) performing household chores vs sweeping the floor; (ii) shopping for groceries vs visiting a friend in the same village; and (iii) managing money vs taking a trip out of town
Distribution of health outcomes according to the baseline SNI, stratified by sex/gender
| Men | Women | Men | Women | |||||
|---|---|---|---|---|---|---|---|---|
| n (%) or mean (SD) | Mean (SD) | n (%) or mean (SD) | n (%) or mean (SD) | n (%) or mean (SD) | n (%) or mean (SD) | |||
| Yes | 497 (16) | 4.19 (1.13) | 134 (47) | 152 (53) | 107 (51) | 104 (49) | ||
| No | 2563 (84) | 4.14 (1.14) | 756 (49) | 790 (51) | 480 (47) | 537 (53) | 0.353 | |
| Yes | 95 (3) | 3.97 (1.02) | 22 (35) | 41 (65) | 20 (63) | 12 (37) | ||
| No | 2965 (97) | 4.16 (1.14) | 868 (49) | 909 (51)* | 567 (48) | 621 (52) | 0.211 | |
| Yes | 67 (2) | 3.74 (1.06) | 26 (51) | 25 (49) | 10 (63) | 6 (38) | ||
| No | 2993 (98) | 4.16 (1.14)* | 864 (48) | 925 (52) | 577 (48) | 627 (52) | 0.007 | |
| Yes | 21 (1) | 4.9 (0.89) | 3 (43) | 4 (57) | 6 (43) | 8 (57) | ||
| No | 3039 (99) | 4.15 (1.14)* | 887 (48) | 938 (52) | 581 (48) | 633 (52) | 0.012 | |
| Yes | 205 (7) | 4.32 (1.17) | 52 (49) | 55 (51) | 51 (52) | 47 (48) | ||
| No | 2855 (93) | 4.14 (1.14)* | 838 (48) | 895 (52) | 536 (48) | 586 (52) | 0.016 | |
| Yes | 132 (4) | 4.19 (1.17) | 42 (51) | 41 (49) | 24 (49) | 25 (51) | ||
| No | 2928 (96) | 4.15 (1.13) | 848 (48) | 909 (52) | 563 (48) | 608 (52) | 0.510 | |
| Yes | 71 (2) | 4.27 (1.12) | 23 (61) | 15 (39) | 16 (48) | 17 (52) | ||
| No | 2989 (98) | 4.15 (1.14) | 867 (48) | 935 (52) | 571 (48) | 616 (52) | 0.250 | |
| Mean level (%) | 5.89 (1.23) | – | 5.88 (1.19) | 5.83 (1.12) | 5.94 (1.21) | 5.94 (1.43) | 0.201 | |
| Prediabetes, diabetes level | 670 (46) | 4.18 (1.14) | 189 (48) | 205 (52) | 136 (49) | 140 (51) | ||
Normal levels | 772 (54) | 4.16 (1.14) | 215 (47) | 245 (53) | 141 (45) | 171 (55) | 0.764 | |
| Hypertensive | 1796 (59) | 4.11 (1.15) | 487 (44) | 612 (56) | 302 (43) | 395 (57) | ||
| Normotensive | 1264 (41) | 4.21 (1.12)* | 403 (54) | 338 (46)* | 285 (54) | 238 (46)* | 0.153 | |
| Mean level (mg/l) | 2.21 (4.22) | – | 2.30 (5.44) | 2.10 (3.67) | 1.95 (3.35) | 2.48 (3.82) | 0.854 | |
| Medium or high risk level | 658 (45) | 4.24 (1.16) | 162 (43) | 211 (57) | 122 (43) | 163 (57) | ||
Low risk level | 799 (55) | 4.12 (1.12)* | 245 (50) | 244 (50)* | 158 (51) | 152 (49)* | 0.081 | |
| Mean strengths (kg) | 21.05 (7.53) | – | 25.75 (6.59) | 16.02 (4.80)* | 26.63 (6.47) | 16.81 (4.87)* | 0.004 | |
| Yes | 402 (13) | 4.17 (1.11) | 83 (35) | 156 (65) | 55 (34) | 108 (66) | ||
| No | 2658 (87) | 4.14 (1.14) | 807 (50) | 794 (50)* | 532 (50) | 525 (50)* | 0.766 | |
| Yes | 345 (11) | 4.31 (1.14) | 84 (45) | 104 (55) | 66 (42) | 91 (58) | ||
| No | 2715 (89) | 4.13 (1.13)* | 806 (49) | 846 (51) | 521 (49) | 542 (51) | 0.023 | |
| Yes | 1043 (34) | 4.03 (1.17) | 219 (33) | 454 (67) | 121 (33) | 249 (67) | < 0.001 | |
| No | 2017 (66) | 4.22 (1.12)* | 671 (58) | 496 (42)* | 466 (55) | 384 (45)* | ||
| Yes | 1140 (37) | 4.06 (1.15) | 246 (35) | 467 (66) | 168 (39) | 259 (61) | ||
| No | 1920 (63) | 4.21 (1.13)* | 644 (57) | 483 (43)* | 419 (53) | 374 (47)* | 0.036 | |
| Mean number of words recalled (range: 0–10) | 3.08 (1.52) | – | 3.06 (1.47) | 2.83 (1.53)* | 3.35 (1.54) | 3.24 (1.48) | < 0.001 | |
| Mean score (range: 0–8) | 3.06 (2.01) | – | 3.17 (2.03) | 2.76 (1.85)* | 3.53 (2.11) | 2.93 (2.00)* | 0.005 | |
| Mean score (range: 5–25) | 5.37 (1.29) | – | 5.34 (1.36) | 5.56 (1.62)* | 5.24 (0.87) | 5.28 (0.88) | < 0.001 | |
| Any ADL limitation(s) | 377 (12) | 3.95 (1.15) | 92 (36) | 161 (64) | 53 (43) | 71 (57) | ||
| No ADL limitations | 2683 (88) | 4.18 (1.13)* | 798 (50) | 789 (50)* | 534 (49) | 562 (51) | 0.003 | |
| Mean score (range: 6–30) | 7.50 (3.63) | – | 7.83 (3.99) | 7.75 (4.03)* | 7.25 (3.11) | 6.91 (2.72)* | < 0.001 | |
| Any IADL limitation(s) | 715 (23) | 4.01 (1.12) | 239 (50) | 235 (50) | 131 (54) | 110 (46) | ||
| No IADL limitations | 2345 (77) | 4.20 (1.14)* | 651 (48) | 715 (52) | 456 (47) | 523 (53)* | < 0.001 | |
Annotations Table 3:
1) *(asterix) indicates a statistical difference (p < 0.05) of the mean SNI score between respondents with good vs bad health outcomes (column 3) and between men and women within each SNI group (columns 5 and 7)
2) The p-value (column 8) indicates a statistical difference between respondents with a low vs a high SNI
Note: p-values obtained from chi-squared tests for proportions and t-tests for means. Source: IFLS
Fig. 1Results from the multivariable regression adjustment (RA) models for men (blue/diamond) and women (red/circle). Annotation Figure 1: The following confidence intervals (CIs) were truncated to a − 2 to 2 interval: lung diseases (women) 95% CI (0.1452047–2.002185); cancer (men) 95% CI (−2.302062–0.5509206); and cancer (women) 95% CI (− 2.191686–0.3012024). All the models were controlled for age, education, household per capita expenditure, residential stability, area of residence, physical activity, smoking, BMI, SRH, depression, health check-up in the past 5 years, health insurance coverage, baseline NCDs, and disability
Fig. 2Results from the propensity score matching (PSM) models for men (blue/diamond) and women (red/circle). Annotation Figure 2: The following confidence interval (CI) was truncated to a − 1 to 1 interval: grip strengths (men) 95% CI (− 0.2499284–1.17726). All the models were matched on baseline age, education, household per capita expenditure, residential stability, area of residence, physical activity, smoking, BMI, SRH, depression, health check-up in the past 5 years, health insurance coverage, NCDs, and disability
Fig. 3Results from the instrumental variable (IV) analysis models for men (blue/diamond) and women (red/circle). Annotation Figure 3: The following confidence intervals (CIs) were truncated to a − 10 to 10 interval: grip strengths (women) 95% CI (− 24.97352–12.64874); episodic memory (women) 95% CI (− 0.1034597–12.91134); visuospatial abilities (men) 95% CI (− 0.4174638–15.87406); ADLs (women) 95% CI (− 15.05158–4.946002); and IADLs (women): − 13.60297 (− 40.19411–12.98818). All the models were controlled for age, education, household per capita expenditure, area of residence, physical activity, smoking, BMI, SRH, depression, health check-up in the past 5 years, health insurance coverage, baseline NCDs, and disability; IV = residential stability (tests of endogeneity: Durbin (p = 0.049), Wu–Hauser (p = 0.045); instrument strengths F = 19.58 (p = 0.002)
Results from regression adjustment (RA), propensity score matching (PSM), and instrumental variable analysis models (IV) for effects of baseline SNI on various subsequent adult health outcomes for the total sample and stratified by sex/gender
| Health outcomes | Total sample ( | Women ( | Men ( | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RA | PSM | IV | RA | PSM | IV | RA | PSM | IV | ||||||||||
| NCD morbidity | 0.12 | 0.411 | 0.029 | 0.480 | −0.146 | 0.499 | 0.26 | 0.126 | 0.029 | 0.052 | −0.672 | 0.447 | −0.04 | 0.633 | 0.004 | 0.904 | −0.013 | 0.950 |
| Asthma | 0.19 | 0.410 | 0.008 | 0.383 | 0.070 | 0.502 | −0.118 | 0.729 | − 0.34 | 0.196 | − 0.007 | 0.171 | 0.146 | 0.196 | ||||
| Other lung diseases | 0.089 | 0.315 | − 0.019 | 0.940 | 0.63 | 0.103 | 0.013 | 0.064 | 0.111 | 0.262 | ||||||||
| Cancer, malignant tumours | − 0.004 | 0.082 | − 0.084 | 0.123 | − 0.95 | 0.142 | − 0.006 | 0.179 | − 0.165 | 0.424 | −0.87 | 0.213 | −0.006 | 0.234 | −0.062 | 0.224 | ||
| Diabetes | −0.04 | 0.296 | 0.004 | 0.370 | 0.078 | 0.590 | 0.04 | 0.517 | 0.006 | 0.882 | 0.389 | 0.478 | −0.13 | 0.357 | 0.010 | 0.985 | −0.039 | 0.792 |
| Cardiovascular diseases | 0.018 | 0.134 | −0.114 | 0.362 | 0.27 | 0.177 | 0.014 | 0.104 | −0.165 | 0.669 | 0.43 | 0.128 | 0.016 | 0.224 | −0.103 | 0.427 | ||
| Stroke | 0.05 | 0.844 | −0.001 | 0.862 | −0.019 | 0.829 | −0.09 | 0.859 | −0.001 | 0.805 | −0.538 | 0.309 | 0.12 | 0.774 | −0.009 | 0.605 | 0.129 | 0.223 |
| HbA1c levels | −0.10 | 0.988 | 0.041 | 0.837 | 0.842 | 0.829 | 0.18 | 0.970 | 0.060 | 0.732 | −1.202 | 0.492 | 0.04 | 0.972 | −0.030 | 0.770 | 0.052 | 0.927 |
| Hypertension | 0.03 | 0.155 | 0.004 | 0.115 | 0.466 | 0.138 | −0.08 | 0.594 | −0.025 | 0.914 | 0.981 | 0.408 | 0.12 | 0.232 | 0.026 | 0.201 | 0.301 | 0.331 |
| CRP levels | −0.21 | 0.063 | 1.908 | 0.746 | −0.09 | 0.247 | −1.249 | 0.480 | −0.32 | 0.192 | −0.065 | 0.214 | 0.088 | 0.351 | ||||
| Grip strengths | 0.19 | 0.364 | 0.330 | 0.068 | −2.959 | 0.370 | 0.07 | 0.806 | −0.260 | 0.890 | −6.162 | 0.524 | 0.38 | 0.246 | 0.464 | 0.326 | −2.099 | 0.578 |
| Arthritis/rheumatism | −0.02 | 0.808 | −0.009 | 0.695 | −0.359 | 0.113 | −0.05 | 0.717 | 0.003 | 0.739 | −1.061 | 0.350 | 0.07 | 0.910 | 0.008 | 0.627 | −0.177 | 0.343 |
| Sensory impairments | −0.09 | 0.576 | −0.005 | 0.660 | 0.107 | 0.563 | −0.12 | 0.531 | −0.023 | 0.271 | 0.564 | 0.455 | −0.04 | 0.990 | −0.010 | 0.740 | 0.014 | 0.938 |
| Upper-body functional limitations | −0.431 | 0.157 | −1.261 | 0.380 | 0.18 | 0.199 | 0.032 | 0.364 | −0.208 | 0.427 | ||||||||
| Lower-body functional limitations | 0.12 | 0.166 | 0.047 | 0.133 | −0.195 | 0.492 | −0.450 | 0.643 | −0.07 | 0.487 | 0.004 | 0.854 | −0.163 | 0.551 | ||||
| Episodic memory | 0.09 | 0.062 | 0.112 | 0.206 | 0.06 | 0.283 | 0.043 | 0.523 | 6.404 | 0.051 | 0.12 | 0.130 | 0.070 | 0.207 | ||||
| Visuospatial abilities | −0.04 | 0.967 | −0.035 | 0.855 | −0.12 | 0.266 | −0.080 | 0.465 | 0.08 | 0.208 | 0.063 | 0.193 | 7.728 | 0.058 | ||||
| ADL limitations | −0.532 | 0.501 | −5.053 | 0.334 | 0.842 | 0.270 | ||||||||||||
| IADL limitations | −4.283 | 0.096 | −13.602 | 0.327 | −1.812 | 0.432 | ||||||||||||
Note: Coef Regression coefficients, ATT Average treatment effects, LATE Local average treatment effects, p p-value (significant results are printed in bold)